Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells

Kai Lee Wang, Shih Min Hsia, Jiun Yih Yeh, Shao Chi Cheng, Paulus S. Wang, Shyi Wu Wang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Endocrine sensitivity, assessed by the expression of estrogen receptor (ER), has long been the predict factor to guide therapeutic decisions. Tamoxifen has been the most successful hormonal treatment in endocrine-sensitive breast cancer. However, in estrogen-insensitive cancer tamoxifen showed less effectiveness than in estrogen-sensitive cancer. It is interesting to develop new drugs against both hormone-sensitive and insensitive tumor. In this present study we examined anticancer effects of evodiamine extracted from the Chinese herb, Evodiae fructus, in estrogen-dependent and -independent human breast cancer cells, MCF-7 and MDA-MB-231 cells, respectively. Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1×10-6 and 1×10-5 M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression). The expression of ER α and β in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis. Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines. It suggests that evodiamine may in part mediate through ER-inhibitory pathway to inhibit breast cancer cell proliferation.

Original languageEnglish
Article numbere67297
JournalPLoS One
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 26 2013

Fingerprint

breast neoplasms
Cells
Breast Neoplasms
estrogens
tamoxifen
Estrogen Receptors
neoplasms
Estrogens
caspase-7
Tamoxifen
new drugs
caspases
Evodia
immunoblotting
Caspase 7
herbs
Neoplasms
cell proliferation
apoptosis
reverse transcriptase polymerase chain reaction

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Wang, K. L., Hsia, S. M., Yeh, J. Y., Cheng, S. C., Wang, P. S., & Wang, S. W. (2013). Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells. PLoS One, 8(6), [e67297]. https://doi.org/10.1371/journal.pone.0067297

Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells. / Wang, Kai Lee; Hsia, Shih Min; Yeh, Jiun Yih; Cheng, Shao Chi; Wang, Paulus S.; Wang, Shyi Wu.

In: PLoS One, Vol. 8, No. 6, e67297, 26.06.2013.

Research output: Contribution to journalArticle

Wang, Kai Lee ; Hsia, Shih Min ; Yeh, Jiun Yih ; Cheng, Shao Chi ; Wang, Paulus S. ; Wang, Shyi Wu. / Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{fa2dc3b9941e42cd9d02bc94deeadca5,
title = "Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells",
abstract = "Endocrine sensitivity, assessed by the expression of estrogen receptor (ER), has long been the predict factor to guide therapeutic decisions. Tamoxifen has been the most successful hormonal treatment in endocrine-sensitive breast cancer. However, in estrogen-insensitive cancer tamoxifen showed less effectiveness than in estrogen-sensitive cancer. It is interesting to develop new drugs against both hormone-sensitive and insensitive tumor. In this present study we examined anticancer effects of evodiamine extracted from the Chinese herb, Evodiae fructus, in estrogen-dependent and -independent human breast cancer cells, MCF-7 and MDA-MB-231 cells, respectively. Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1×10-6 and 1×10-5 M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression). The expression of ER α and β in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis. Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines. It suggests that evodiamine may in part mediate through ER-inhibitory pathway to inhibit breast cancer cell proliferation.",
author = "Wang, {Kai Lee} and Hsia, {Shih Min} and Yeh, {Jiun Yih} and Cheng, {Shao Chi} and Wang, {Paulus S.} and Wang, {Shyi Wu}",
year = "2013",
month = "6",
day = "26",
doi = "10.1371/journal.pone.0067297",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells

AU - Wang, Kai Lee

AU - Hsia, Shih Min

AU - Yeh, Jiun Yih

AU - Cheng, Shao Chi

AU - Wang, Paulus S.

AU - Wang, Shyi Wu

PY - 2013/6/26

Y1 - 2013/6/26

N2 - Endocrine sensitivity, assessed by the expression of estrogen receptor (ER), has long been the predict factor to guide therapeutic decisions. Tamoxifen has been the most successful hormonal treatment in endocrine-sensitive breast cancer. However, in estrogen-insensitive cancer tamoxifen showed less effectiveness than in estrogen-sensitive cancer. It is interesting to develop new drugs against both hormone-sensitive and insensitive tumor. In this present study we examined anticancer effects of evodiamine extracted from the Chinese herb, Evodiae fructus, in estrogen-dependent and -independent human breast cancer cells, MCF-7 and MDA-MB-231 cells, respectively. Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1×10-6 and 1×10-5 M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression). The expression of ER α and β in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis. Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines. It suggests that evodiamine may in part mediate through ER-inhibitory pathway to inhibit breast cancer cell proliferation.

AB - Endocrine sensitivity, assessed by the expression of estrogen receptor (ER), has long been the predict factor to guide therapeutic decisions. Tamoxifen has been the most successful hormonal treatment in endocrine-sensitive breast cancer. However, in estrogen-insensitive cancer tamoxifen showed less effectiveness than in estrogen-sensitive cancer. It is interesting to develop new drugs against both hormone-sensitive and insensitive tumor. In this present study we examined anticancer effects of evodiamine extracted from the Chinese herb, Evodiae fructus, in estrogen-dependent and -independent human breast cancer cells, MCF-7 and MDA-MB-231 cells, respectively. Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1×10-6 and 1×10-5 M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression). The expression of ER α and β in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis. Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines. It suggests that evodiamine may in part mediate through ER-inhibitory pathway to inhibit breast cancer cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=84879486872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879486872&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0067297

DO - 10.1371/journal.pone.0067297

M3 - Article

C2 - 23840656

AN - SCOPUS:84879486872

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e67297

ER -